Now Is A Good Time To Buy Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)

During the last session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares were 0.35 million, with the beta value of the company hitting 2.69. At the end of the trading day, the stock’s price was $29.78, reflecting an intraday loss of -2.36% or -$0.72. The 52-week high for the ARCT share is $43.81, that puts it down -47.11 from that peak though still a striking 41.17% gain since the share price plummeted to a 52-week low of $17.52. The company’s market capitalization is $801.98M, and the average trade volume was 511.50K shares over the past three months.

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information

Arcturus Therapeutics Holdings Inc (ARCT) registered a -2.36% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.36% in intraday trading to $29.78, hitting a weekly high. The stock’s 5-day price performance is 9.24%, and it has moved by 13.15% in 30 days. Based on these gigs, the overall price performance for the year is 5.16%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts

Statistics show that Arcturus Therapeutics Holdings Inc has underperformed its competitors in share price, compared to the industry in which it operates. Arcturus Therapeutics Holdings Inc (ARCT) shares have gone up 32.24% during the last six months, with a year-to-date growth rate less than the industry average at -120.60% against 14.10. In the rating firms’ projections, revenue will increase 7.00% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 21.7M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 46.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.52M and 45.14M respectively. In this case, analysts expect current quarter sales to grow by 106.30% and then jump by 3.50% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.40%. While earnings are projected to return -233.71% in 2024.

ARCT Dividends

Arcturus Therapeutics Holdings Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.